Pembrolizumab plus axitinib is superior to sunitinib for the treatment of patients with treatment-naïve, advanced renal cell carcinoma (RCC), according to the most recent exploratory analysis of data from the KEYNOTE-426 study....
Read More
It’s no question that advancements in the treatment of dry eye were impressive at AAO 2020....
Read More
It’s no question that advancements in the treatment of age-related macular degeneration were...
Read More
People with multiple sclerosis (MS) may expect worsening symptoms with rising average...
Read More
A retrospective analysis found that in patients with muscle-invasive bladder cancer (MIBC)...
Read MoreRadionuclide therapy directed towards prostate-specific membrane antigen (PSMA) demonstrated promising results in men with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC) [1]. A phase 2 trial compared...
Read More
Tyrosine kinase inhibitor axitinib elicited a 31% response rate in a phase 2 clinical trial that...
Read More
A phase 2 trial demonstrated encouraging outcomes from retroperitoneal lymph node dissection...
Read More
A team of researchers reported that socioeconomic, racial/ethnic, and gender factors influence the...
Read More
MRI is non-inferior to CT for the surveillance of stage 1 testicular seminoma. Over a 6-year...
Read More
Of nearly 80,000,000 USD in funding for bladder cancer research between 2017 and 2019,...
Read More
In CheckMate 9ER, patients with renal cell cancer (RCC) treated with nivolumab plus cabozantinib...
Read More
Determination of human papillomavirus (HPV) status should be done routinely at diagnosis of penile...
Read More
Cure rates for patients with poor- and intermediate-risk metastatic germ cell tumors lag behind...
Read More
Interim data from a clinical trial investigating the efficacy of enfortumab vedotin (EV) on...
Read More
The Institute of Cancer Research in the UK found that the implementation of gemcitabine-platinum...
Read MoreIn patients with advanced RCC, second-line treatment with LEN + EVE prolonged progression-free survival (PFS) compared with EVE alone. LEN + PEMBRO, also showed preliminary efficacious evidence in a phase 1/2 RCC study. Here, we...
Read MoreThe 2021 Genitourinary (GU) Cancers Symposium, one of the largest conference in genitourinary cancers will be held virtually February 11 to 13, showcasing practice-changing research, diverse speakers, global perspectives, and...
Read MoreTreatment with apalutamide Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer Final analysis from Phase 3 TITAN study demonstrated apalutamide provided statistically...
Read MoreIn high-risk muscle-invasive urothelial carcinoma, the use of nivolumab after surgery cut patients’ risk of disease returning or death by 30% over placebo. The data was released for presentation at the American Society of...
Read More
